APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

PLoS Medicine

Volumn 14, Issue 3, 2017, Pages

  Lanoiselée, Hélène Marie ^a,b   Nicolas, Gaël ^a   Wallon, David ^a   Rovelet Lecrux, Anne ^a   Lacour, Morgane ^a   Rousseau, Stéphane ^a   Richard, Anne Claire ^a   Pasquier, Florence ^c,d   Rollin Sillaire, Adeline ^c,d   Martinaud, Olivier ^a   Quillard Muraine, Muriel ^e   de la Sayette, Vincent ^f   Boutoleau Bretonniere, Claire ^g   Etcharry Bouyx, Frédérique ^h   Chauviré, Valérie ^h   Sarazin, Marie ⁱ   le Ber, Isabelle ^j,k   Epelbaum, Stéphane ^j,k   Jonveaux, Thérèse ^l   Rouaud, Olivier ^m   Ceccaldi, Mathieu ^n,o   Félician, Olivier ^n,o   Godefroy, Olivier ^p   Formaglio, Maite ^q   Croisile, Bernard ^q   Auriacombe, Sophie ^r   Chamard, Ludivine ^s   Vincent, Jean Louis ^c   Sauvée, Mathilde ^t   Marelli Tosi, Cecilia ^u   Gabelle, Audrey ^u   Ozsancak, Canan ^b   Pariente, Jérémie ^v   Paquet, Claire ^w   Hannequin, Didier ^a   Campion, Dominique ^a,x   more..

^a UNIVERSITÉ DE ROUEN   (France)

^b Orleans Regional Hospital   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ University Hospital of Sainte Anne   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l UNIVERSITY HOSPITAL OF NANCY   (France)

^m DIJON UNIVERSITY HOSPITAL   (France)

ⁿ AIX MARSEILLE UNIVERSITÉ   (France)

^o TIMONE HOSPITAL   (France)

^p AMIENS UNIVERSITY HOSPITAL   (France)

^q HOSPICES CIVILS DE LYON   (France)

^r BORDEAUX UNIVERSITY HOSPITAL   (France)

^s UNIVERSITY HOSPITAL OF BESANÇON   (France)

^t GRENOBLE UNIVERSITY HOSPITAL   (France)

^u MONTPELLIER UNIVERSITY HOSPITAL   (France)

^v TOULOUSE UNIVERSITY HOSPITAL   (France)

^w HÔPITAL LARIBOISIÈRE   (France)

^x CHS du Rouvray   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN; APP PROTEIN, HUMAN; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN;

ADULT; ALZHEIMER DISEASE; AMYLOID PROTEIN PRECURSOR GENE; ARTICLE; CEREBROSPINAL FLUID; DNA EXTRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPATHOLOGY; POLYMERASE CHAIN REACTION; PRESENILIN 1 GENE; PRESENILIN 2 GENE; FRANCE; GENETICS; MUTATION; ONSET AGE;

ADULT; AGE OF ONSET; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; FRANCE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MUTATION; PRESENILIN-1; PRESENILIN-2;

EID: 85016643182     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002270     Document Type: Article

References (44)

1. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. American journal of human genetics. 1999;65(3):664–70. doi: 10.1086/302553 10441572
2. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375(6534):754–60. doi: 10.1038/375754a0 7596406
3. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, et al. A familial Alzheimer's disease locus on chromosome 1. Science. 1995;269(5226):970–3. 7638621
4. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376(6543):775–8. doi: 10.1038/376775a0 7651536
5. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Human molecular genetics. 1996;5(7):985–8. 8817335
6. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991;353(6347):844–6. doi: 10.1038/353844a0 1944558
7. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704–6. doi: 10.1038/349704a0 1671712
8. Carter DA, Desmarais E, Bellis M, Campion D, Clerget-Darpoux F, Brice A, et al. More missense in amyloid gene. Nature genetics. 1992;2(4):255–6. doi: 10.1038/ng1292-255 1303275
9. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature genetics. 2006;38(1):24–6. doi: 10.1038/ng1718 16369530
10. Haass C, Kaether C, Thinakaran G, Sisodia S, Trafficking and proteolytic processing of APP. Cold Spring Harbor perspectives in medicine. 2012;2(5):a006270. doi: 10.1101/cshperspect.a006270 22553493
11. Campion D, Pottier C, Nicolas G, Le Guennec K, Rovelet-Lecrux A, Alzheimer disease: modeling an Abeta-centered biological network. Molecular psychiatry. 2016;21(7):861–71. doi: 10.1038/mp.2016.38 27021818
12. Guerreiro RJ, Baquero M, Blesa R, Boada M, Bras JM, Bullido MJ, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of aging. 2010;31(5):725–31. doi: 10.1016/j.neurobiolaging.2008.06.012 18667258
13. Moulder KL, Snider BJ, Mills SL, Buckles VD, Santacruz AM, Bateman RJ, et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimer's research & therapy. 2013;5(5):48.
14. Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Marechal L, Martinaud O, et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. Journal of Alzheimer's disease: JAD. 2012;30(4):847–56. doi: 10.3233/JAD-2012-120172 22475797
15. Nicolas G, Wallon D, Charbonnier C, Quenez O, Rousseau S, Richard AC, et al. Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. European journal of human genetics: EJHG. 2016;24(5):710–6. doi: 10.1038/ejhg.2015.173 26242991
16. Acuna-Hidalgo R, Veltman JA, Hoischen A, New insights into the generation and role of de novo mutations in health and disease. Genome biology. 2016;17(1):241. doi: 10.1186/s13059-016-1110-1 27894357
17. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr.Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2011;7(3):263–9.
18. Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, et al. A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's research & therapy. 2014;6(3):38.
19. Sellal F, Wallon D, Martinez-Almoyna L, Marelli C, Dhar A, Oesterle H, et al. APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review. Journal of Alzheimer's disease: JAD. 2017;56(1):37–46. doi: 10.3233/JAD-160709 27858710
20. Rovelet-Lecrux A, Charbonnier C, Wallon D, Nicolas G, Seaman MN, Pottier C, et al. De novo deleterious genetic variations target a biological network centered on Abeta peptide in early-onset Alzheimer disease. Molecular psychiatry. 2015;20(9):1046–56. doi: 10.1038/mp.2015.100 26194182
21. Raux G, Guyant-Marechal L, Martin C, Bou J, Penet C, Brice A, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. Journal of medical genetics. 2005;42(10):793–5. doi: 10.1136/jmg.2005.033456 16033913
22. Portet F, Dauvilliers Y, Campion D, Raux G, Hauw JJ, Lyon-Caen O, et al. Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu). Neurology. 2003;61(8):1136–7. 14581682
23. Dumanchin C, Brice A, Campion D, Hannequin D, Martin C, Moreau V, et al. De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. Journal of medical genetics. 1998;35(8):672–3. 9719376
24. Dumanchin C, Tournier I, Martin C, Didic M, Belliard S, Carlander B, et al. Biological effects of four PSEN1 gene mutations causing Alzheimer disease with spastic paraparesis and cotton wool plaques. Human mutation. 2006;27(10):1063.
25. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91. doi: 10.1038/nature19057 27535533
26. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253–60. doi: 10.1212/WNL.0000000000000596 24928124
27. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Human mutation. 2006;27(7):686–95. doi: 10.1002/humu.20336 16752394
28. Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Annals of neurology. 2007;61(5):446–53. doi: 10.1002/ana.21099 17366635
29. Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS ONE. 2012;7(2):e31039. doi: 10.1371/journal.pone.0031039 22312439
30. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Human molecular genetics. 1998;7(1):43–51. 9384602
31. Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, et al. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. American journal of human genetics. 2000;66(1):110–7. doi: 10.1086/302702 10631141
32. Sleegers K, Roks G, Theuns J, Aulchenko YS, Rademakers R, Cruts M, et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain: a journal of neurology. 2004;127(Pt 7):1641–9.
33. Brouwers N, Sleegers K, Van Broeckhoven C, Molecular genetics of Alzheimer's disease: an update. Annals of medicine. 2008;40(8):562–83. doi: 10.1080/07853890802186905 18608129
34. To MD, Gokgoz N, Doyle TG, Donoviel DB, Knight JA, Hyslop PS, et al. Functional characterization of novel presenilin-2 variants identified in human breast cancers. Oncogene. 2006;25(25):3557–64. doi: 10.1038/sj.onc.1209397 16474849
35. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I, Familial Alzheimer disease associated with A713T mutation in APP. Neuroscience letters. 2004;370(2–3):241–3. doi: 10.1016/j.neulet.2004.08.026 15488330
36. Rossi G, Giaccone G, Maletta R, Morbin M, Capobianco R, Mangieri M, et al. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology. 2004;63(5):910–2. 15365148
37. Bernardi L, Geracitano S, Colao R, Puccio G, Gallo M, Anfossi M, et al. AbetaPP A713T mutation in late onset Alzheimer's disease with cerebrovascular lesions. Journal of Alzheimer's disease: JAD. 2009;17(2):383–9. doi: 10.3233/JAD-2009-1061 19363265
38. Conidi ME, Bernardi L, Puccio G, Smirne N, Muraca MG, Curcio SA, et al. Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family. Neurology. 2015;84(22):2266–73. doi: 10.1212/WNL.0000000000001648 25948718
39. Barber IS, Garcia-Cardenas JM, Sakdapanichkul C, Deacon C, Zapata Erazo G, Guerreiro R, et al. Screening exons 16 and 17 of the amyloid precursor protein gene in sporadic early-onset Alzheimer's disease. Neurobiology of aging. 2016;39:220 e1–7.
40. Golan MP, Styczynska M, Jozwiak K, Walecki J, Maruszak A, Pniewski J, et al. Early-onset Alzheimer's disease with a de novo mutation in the presenilin 1 gene. Experimental neurology. 2007;208(2):264–8. doi: 10.1016/j.expneurol.2007.08.016 17931627
41. Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, et al. A framework for the interpretation of de novo mutation in human disease. Nature genetics. 2014;46(9):944–50. doi: 10.1038/ng.3050 25086666
42. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al. Impact of the 2008–2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. Journal of Alzheimer's disease: JAD. 2013;34(1):297–305. doi: 10.3233/JAD-121549 23186986
43. Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Molecular psychiatry. 2012;17(9):875–9. doi: 10.1038/mp.2012.15 22472873
44. Nicolas G, Charbonnier C, Wallon D, Quenez O, Bellenguez C, Grenier-Boley B, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Molecular psychiatry. 2016;21(6):831–6. doi: 10.1038/mp.2015.121 26303663